SSTR5 somatostatin receptor 5
ENSG00000162009 · protein coding · Open Targets profile
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization. {ECO:0000269|PubMed:12072395, ECO:0000269|PubMed:7908405, ECO:0000269|PubMed:8078491, ECO:0000269|PubMed:8373420}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 2.982599973678589 (upper bound 14.14900016784668). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 216 registry trials, updated in the last three years, of the most advanced drugs against SSTR5 (lanreotide, pasireotide pamoate, pasireotide, somatostatin, octreotide, lutetium oxodotreotide lu-177, vapreotide, onzigolide, lutetium oxodotreotide, veldoreotide, pasireotide diaspartate), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Frank I LinNational Cancer Institute (NCI) · 3 of 4 trials Phase 2+
- Maddalena SansoviniIRST IRCCS · 3 of 3 trials Phase 2+
- Giovanni PaganelliIRST IRCCS, Meldola (FC) · 2 of 2 trials Phase 2+
- Jana IvanidzeWeill Medical College of Cornell University · 2 of 2 trials Phase 2+
- Jianming XuChinese PLA General Hospital · 2 of 2 trials Phase 2+
- Joanna Klubo-GwiezdzinskaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 2 of 2 trials Phase 2+
- Simron SinghCanadian Cancer Trials Group · 2 of 2 trials Phase 2+
- Lowell B AnthonyOhio State University Comprehensive Cancer Center LAO · 1 of 2 trials Phase 2+
- Nikolaos TrikalinosWashington University School of Medicine · 1 of 2 trials Phase 2+
- Petrus de JongRayzeBio, Inc. · 1 of 2 trials Phase 2+
- Ye YuanRayzeBio, Inc. · 1 of 2 trials Phase 2+
- Andrea FrasoldatiDepartment of Endocrinology, Thyroid Disease Center-Arcispedale Santa Maria Nuova of Reggio Emilia, Reggio Emilia, Italy. · 1 of 1 trials Phase 2+
- Andrea FrillingImperial College London · 1 of 1 trials Phase 2+
- Anna C PavlickSandra and Edward Meyer Cancer Center at Weill Cornell Medicine · 1 of 1 trials Phase 2+
- Armando FroioNuclear Medicine Unit, Santa Maria Nuova Hospital · 1 of 1 trials Phase 2+
Registry trials of lanreotide, pasireotide pamoate, pasireotide, somatostatin, octreotide, lutetium oxodotreotide lu-177, vapreotide, onzigolide, lutetium oxodotreotide, veldoreotide, pasireotide diaspartate updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 165 of 209 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 7 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
105 trials of drugs against SSTR5 were stopped early; 15 give no reason
Terminated, withdrawn and suspended interventional trials of lanreotide, pasireotide pamoate, pasireotide, somatostatin, octreotide, lutetium oxodotreotide lu-177, vapreotide, onzigolide, lutetium oxodotreotide, veldoreotide, pasireotide diaspartate, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 105.
- suspended · 2026-10-29 · Azienda Ospedaliero Universitaria Maggiore della Carita · matched by the registry's drug synonyms“ethical issue”
- withdrawn · 2026-10-13 · University of Alabama at Birmingham · Octreotide (drug)“Project terminated due to loss of sponsor funding following the dissolution of AMD Opti.”
- terminated · 2026-09-03 · AHS Cancer Control Alberta · matched by the registry's drug synonyms“The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is considered standard of care. Furthermore, the manufacturer of the study Investigational Product (IP) is no longer supplying the IP.”
- withdrawn · 2026-08-31 · Weill Medical College of Cornell University · matched by the registry's drug synonyms“Funding has not been solidified for the initiation of the study.”
- terminated · 2026-08-07 · Alexion Pharmaceuticals, Inc. · matched by the registry's drug synonyms“This decision is based on strategic portfolio prioritization”
- suspended · 2026-07-27 · AHS Cancer Control Alberta · matched by the registry's drug synonyms“Study closed to accrual given widespread availability of the similar marketed product, Lutathera(R), and the corresponding lack of accrual to the study.”
- terminated · 2026-07-15 · Crinetics Pharmaceuticals Inc. · matched by the registry's drug synonyms“The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).”
- suspended · 2026-05-22 · National Cancer Centre, Singapore · matched by the registry's drug synonyms“Seeking further funding before resuming the study.”
- suspended · 2026-04-03 · Mayo Clinic · Somatostatin analog“study paused for interim analysis”
- terminated · 2026-02-05 · Ariceum Therapeutics GmbH · matched by the registry's drug synonyms“Study terminated due to strategic business decisions.”
- terminated · 2026-01-21 · National Cancer Institute (NCI) · Octreotide“This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.”
- terminated · 2026-01-14 · Imperial College London · matched by the registry's drug synonyms“The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.”
- terminated · 2025-11-20 · Medical University of South Carolina · Octreotide“Recruitment was severely affected due to COVID, so study was stopped prematurely.”
- terminated · 2025-11-17 · Debiopharm International SA · matched by the registry's drug synonyms“The recruitment was halted for strategic reasons”
- terminated · 2025-06-10 · Orano Med LLC · matched by the registry's drug synonyms“Terminated for non-safety reasons.”
- terminated · 2025-06-10 · Erasmus Medical Center · matched by the registry's drug synonyms“the number of dropouts and slow recruitment”
- terminated · 2025-04-30 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Pasireotide“Slow accrual”
- withdrawn · 2025-01-31 · Jules Bordet Institute · matched by the registry's drug synonyms“Sponsor decision”
- terminated · 2025-01-13 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · matched by the registry's drug synonyms“Following the publication in the Official Journal of the reclassification of the drug LUTATHERA in band H, it was decided to close the enrolment early on 30/Aug/19.”
- terminated · 2025-01-13 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · matched by the registry's drug synonyms“Enrollment target not reached”
- withdrawn · 2024-10-26 · University of Chicago · matched by the registry's drug synonyms“0 enrollment”
- withdrawn · 2024-07-10 · Columbia University · Octreotide Acetate“Investigators' scientific priorities shifted.”
- withdrawn · 2024-04-29 · David Bushnell · matched by the registry's drug synonyms“Azedra withdrawn from US market”
- withdrawn · 2024-03-06 · University of California, Los Angeles · Octreotide“Funding issues; the study was never started”
- terminated · 2024-02-14 · Fox Chase Cancer Center · Octreotide“Grantor closed study”
Paediatric incentives and obligations for SSTR5's drugs
For lanreotide, pasireotide pamoate, pasireotide, somatostatin, octreotide, lutetium oxodotreotide lu-177, vapreotide, onzigolide, lutetium oxodotreotide, veldoreotide, pasireotide diaspartate: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · SSTR5 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002950-PIP01-20-M01 (lutetium (177Lu) oxodotreotide, Treatment of gastroenteropancreatic neuroendocrine tumours): PM: decision on the application for modification of an agreed PIP, 1 Dec 2023; compliance positive 18 Oct 2024; EMEA-001503-PIP01-13 (Lanreotide acetate, Treatment of acromegaly;Treatment of gastrointestinal fistulae;Treatment of metastases to peritoneum;Treatment of pituitary gigantism;Treatment of pituitary neoplasms): W: decision granting a waiver in all age groups for all conditions or indications, 29 Nov 2013; EMEA-000464-PIP02-10 (pasireotide, Treatment of acromegaly and pituitary gigantism): W: decision granting a waiver in all age groups for all conditions or indications, 24 Sept 2010; EMEA-000464-PIP01-08 (pasireotide, Overproduction of pituitary ACTH;Pituitary dependant Cushing's disease;Pituitary dependant hyperadrenocorticism): W: decision granting a waiver in all age groups for all conditions or indications, 20 Apr 2009Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/07/523 positive 31 Jan 2008: Treatment of gastro-entero-pancreatic neuroendocrine tumours; EU/3/25/3093 positive 18 Jul 2025: Treatment of autosomal dominant polycystic kidney disease; EU/3/09/645 withdrawn 12 Jun 2009: Treatment of acromegaly; EU/3/13/1170 withdrawn 5 Aug 2013: Treatment of acromegaly; +8 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Lutathera: authorised since 26 Sept 2017, orphan medicine; Signifor: authorised since 24 Apr 2012; Oczyesa: authorised since 30 Jun 2025; Mycapssa: withdrawn since 2 Dec 2022Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of lanreotide, pasireotide pamoate, pasireotide, somatostatin, octreotide, lutetium oxodotreotide lu-177, vapreotide, onzigolide, lutetium oxodotreotide, veldoreotide, pasireotide diaspartateRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 54 interventional studies of lanreotide, pasireotide pamoate, pasireotide, somatostatin, octreotide, lutetium oxodotreotide lu-177, vapreotide, onzigolide, lutetium oxodotreotide, veldoreotide, pasireotide diaspartate include patients under 18; 16 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 13 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.